http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
-
Greenwich LifeSciences delays annual filing amid audit completion
-
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
-
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
-
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
-
Greenwich LifeSciences presents immunotherapy trial data at cancer meeting
-
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
-
Greenwich LifeSciences reports Q1 cash balance of $10.5 million
-
Greenwich LifeSciences Provides Update on Financing Strategy
-
Greenwich LifeSciences files patent claims to expand GLSI-100 eligibility
-
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
-
Greenwich LifeSciences adds City of Hope to breast cancer trial
-
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
-
Greenwich LifeSciences to present FLAMINGO-01 trial data at AACR meeting
-
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
-
Greenwich LifeSciences reports reduced breast cancer recurrence rates
-
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01
-
Greenwich LifeSciences begins using commercial GP2 in breast cancer trial
-
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
-
Greenwich LifeSciences reports 33% increase in FLAMINGO-01 screening rate
-
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
-
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
-
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
-
Greenwich LifeSciences raises cash balance to $12.5 million through ATM
-
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
-
FDA approves Greenwich LifeSciences commercial GP2 for FLAMINGO-01 trial
-
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
-
Greenwich LifeSciences extends director lock-up to September 2026
-
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
-
Greenwich LifeSciences reports progress on FLAMINGO-01 breast cancer trial
-
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
-
Greenwich LifeSciences reports 80% recurrence reduction in cancer trial
-
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
-
Greenwich LifeSciences completes enrollment in open label arm of phase III trial
-
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01Â
-
Greenwich LifeSciences screens over 1,000 patients in phase III trial
-
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
-
Greenwich LifeSciences adds Austria to Phase III breast cancer trial
-
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
-
Greenwich LifeSciences expands breast cancer trial to Belgium
-
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
-
Greenwich LifeSciences expands FLAMINGO-01 trial to Portugal
-
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
-
Greenwich LifeSciences expands breast cancer trial to Ireland
-
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
-
Greenwich LifeSciences gets FDA fast track status for breast cancer drug
-
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
-
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
-
Greenwich LifeSciences builds internal clinical operations team
-
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
